GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Klotho Neurosciences Inc (NAS:KLTO) » Definitions » Earnings Yield (Joel Greenblatt) %

KLTO (Klotho Neurosciences) Earnings Yield (Joel Greenblatt) % : -43.48% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Klotho Neurosciences Earnings Yield (Joel Greenblatt) %?

Klotho Neurosciences's Enterprise Value for the quarter that ended in Dec. 2024 was $13.34 Mil. Klotho Neurosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-5.79 Mil. Klotho Neurosciences's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2024 was -43.48%.

The historical rank and industry rank for Klotho Neurosciences's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

KLTO' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -103.09   Med: 0   Max: 0
Current: -103.09

KLTO's Earnings Yield (Joel Greenblatt) % is ranked worse than
80.18% of 1312 companies
in the Biotechnology industry
Industry Median: -13.255 vs KLTO: -103.09

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Klotho Neurosciences's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Klotho Neurosciences Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Klotho Neurosciences's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Klotho Neurosciences Earnings Yield (Joel Greenblatt) % Chart

Klotho Neurosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Earnings Yield (Joel Greenblatt) %
- - - -43.48

Klotho Neurosciences Quarterly Data
Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -3.20 -29.50 -43.48

Competitive Comparison of Klotho Neurosciences's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Klotho Neurosciences's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Klotho Neurosciences's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Klotho Neurosciences's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Klotho Neurosciences's Earnings Yield (Joel Greenblatt) % falls into.


;
;

Klotho Neurosciences Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Klotho Neurosciencess Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2024 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-5.794/13.342285
=-43.43 %

Klotho Neurosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.79 Mil.



Klotho Neurosciences  (NAS:KLTO) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Klotho Neurosciences Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Klotho Neurosciences's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Klotho Neurosciences Business Description

Industry
Traded in Other Exchanges
N/A
Address
13576 Walnut Street, Suite A, Omaha, NE, USA, 68144
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.